Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001590:Benztropine / Q000627:therapeutic use; D002389:Catatonia / Q000139:chemically induced; D003128:Coma / Q000139:chemically induced; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005334:Fever / Q000139:chemically induced; D005476:Fluphenazine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009069:Movement Disorders / Q000139:chemically induced*; D009127:Muscle Rigidity / Q000139:chemically induced*; D010640:Phenothiazines / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D013577:Syndrome
D010640:Phenothiazines; D001590:Benztropine; D003402:Creatine Kinase; D005476:Fluphenazine